Ignite Creation Date:
2024-05-05 @ 11:48 AM
Last Modification Date:
2024-10-26 @ 9:14 AM
Study NCT ID:
NCT00138775
Status:
UNKNOWN
Last Update Posted:
2006-12-27
First Post:
2005-08-28
Brief Title:
Israel Multicenter D-Serine Study IMSER for the Treatment of Schizophrenia
Sponsor:
Sheba Medical Center
Organization:
Sheba Medical Center
Study Overview
Official Title:
D-Serine Adjuvant Pharmacotherapy for the Treatment of Schizophrenia
Status:
UNKNOWN
Status Verified Date:
2006-10
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The goal of the present study is to evaluate the effect of D-serine added to antipsychotic treatment on negative and cognitive symptoms in schizophrenia
The investigators are hypothesizing that D-serine will improve cognitive functioning and negative symptoms
The investigators are hypothesizing that D-serine will improve cognitive functioning and negative symptoms
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None